摘要
增生平是由中国医学科学院肿瘤研究所研制的纯中药制剂,其主要用于阻断食管癌前病变、提高食管贲门癌术后患者生存期,同时也逐步应用在治疗口腔黏膜白斑、逆转慢性萎缩性胃炎肠化生及降低四肢骨巨细胞瘤术后复发率等方面。增生平的抗肿瘤机制主要与调控Notch信号通路、促进肿瘤细胞凋亡、抑制肿瘤细胞增殖等有关。其药物组成中的山豆根及白鲜皮所含有的梣酮、白鲜碱、高丽槐素、黄柏酮、苦参碱等有效成分可能发挥了主要的抗肿瘤活性。目前增生平的相关基础研究仍局限在探究其对肿瘤细胞内相关分子表达的影响,其在肿瘤微环境当中的作用仍有待进一步阐释;同时,相关临床研究大多存在患者数少,研究设计缺乏严谨性等问题,故多中心、大样本的随机对照实验还有待进一步展开。
Zengshengping is a pure traditional Chinese medicine preparation which was developed by Cancer Institute of Chinese Academy of Medical Sciences.It is mainly used to block the precancerous lesion of the esophagus,improve the postoperative survival time of patients with esophageal and cardiac cancer,and gradually apply in the treatment of oral leukoplakia,reverse the chronic atrophic gastritis intestinal metaplasia and reduce the recurrence rate of postoperative of giant cell tumor of bone in extremities.The anti-tumor mechanism of Zengshengping is mainly related to regulation of Notch signaling pathway,promotion of tumor cell apoptosis,and inhibition of tumor cell proliferation.The active components of the medicinal components,such asfraxinellone,dictamnine,maackiain,obacunone and matrine in Sophorae Tonkinensis Radix Et Rhizoma and Dictamni Cortex,may play the main anti-tumor activity.At present,the relevant basic research of Zengshengping is still limited to exploring its influence on the expression of relevant molecules in tumor cells,and its role in tumor microenvironment remains to be further explained.At the same time,most of the relevant clinical studies have problems such as a small number of patients and a lack of rigor in the study design,so the multi-center,large-sample randomized controlled trials need to be further carried out.
作者
刘思达
邓博
陈冬梅
贾立群
LIU Sida;DENG Bo;CHEN Dongmei;JIA Liqun(School of Clinical Medicine,Beijing University of Chinese Medicine(China-Japan Friendship Hospital),Beijing100029,China;Department of Oncology of Integrative Chinese and Western Medicine,China-Japan Friendship Hospital,Beijing100029,China)
出处
《中国医药导报》
CAS
2021年第2期31-34,共4页
China Medical Herald
基金
国家中医药管理局重大疑难疾病中西医临床协作能力建设项目(国中医药办医政函〔2018〕275号)。
关键词
增生平
肿瘤
综述
Zengshengping
Tumor
Review
